Latest News and Press Releases
Want to stay updated on the latest news?
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and...
-
Second quarter revenue of $26.1 million, an increase of 36% compared to prior year periodContinued growth from both the Tuberculosis and Tick-borne disease franchisesSuccessful negotiation of a...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLCĀ (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLCĀ (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and...
-
First quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on...